XTRA:FREHealthcare
Does Fresenius SE KGaA's (XTRA:FRE) EASYGEN Consortium Signal a Shift in Oncology Innovation Strategy?
Fresenius recently announced the launch of the EASYGEN consortium, uniting industry and academic partners to accelerate and streamline CAR-T cell therapy manufacturing in Europe with €8 million in EU funding.
This initiative positions Fresenius at the forefront of personalized cancer treatment innovations by aiming to make advanced cell therapies more accessible and cost-effective in hospital settings.
We'll explore how leading a hospital-based CAR-T manufacturing project may influence...